BioCatalystWatch
ALECWorkspace / ALEC / OverviewCompany library
Price
Market cap
Next catalystExpected 1H 2027AL037/AL137 · Trial initiationCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

ADP062

Alpha-synuclein

PreINDP1P2P3FilingApproved
Upcoming / outlook

ADP065

NLRP3

PreINDP1P2P3FilingApproved
Upcoming / outlook

AL137

Antibody

PyroGlu3 Aβ × TfR

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

AL164

MAPT (tau) mRNA

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

ADP037-ABC

Amyloid beta (Aβ)

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

AL164

MAPT (tau) mRNA

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

AL137

Antibody

PyroGlu3 Aβ × TfR

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

ADP062

Alpha-synuclein

PreINDP1P2P3FilingApproved
Upcoming / outlook

ADP065

NLRP3

PreINDP1P2P3FilingApproved
Upcoming / outlook

ADP037-ABC

Amyloid beta (Aβ)

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

Antibody

PyroGlu3 Aβ × TfR

PreINDP1P2P3FilingApproved
AL037/AL137

Antibody

PyroGlu3 Aβ × TfR

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

AL064/AL164

MAPT (tau) mRNA

Partner / License out

History / paused

MS4A

PreINDP1P2P3FilingApproved

TREM2

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ALEC PR & News

PR & News

ALEC SEC archive